Journal of Thrombosis and Thrombolysis

, Volume 28, Issue 3, pp 270–275 | Cite as

Treatment of venous thromboembolism: guidelines translated for the clinician

  • M. Houman Fekrazad
  • Renato D. Lopes
  • Gregg J. Stashenko
  • John H. Alexander
  • David Garcia


Venous thromboembolism is a major cause of morbidity and mortality affecting over 2 million people in the United States each year. The American College of Chest Physicians (ACCP) published their first consensus statement on antithrombotic therapy in 1986, and the most recent guidelines from the ACCP on this topic were released in 2008. We aim to summarize the most recent ACCP guidelines on therapy for venous thromboembolism with practical application and interpretation for the practicing physician. We will briefly review the rating system used in the guidelines for the level of evidence and the strength of the recommendation. We will then discuss the recommendations for initial anticoagulant therapies including low molecular weight heparin, unfractionated heparin, and fondaparinux for patients with both deep vein thrombosis (DVT) and pulmonary embolism (PE). A discussion of the guidelines on duration of anticoagulant therapy with a vitamin K antagonist is also included. In addition, we will address the use of thrombolytic therapy and inferior vena cava filter placement for DVT and PE. Prevention of postphlebitic syndrome is discussed as well. We will conclude with a brief discussion of future directions including several novel therapeutic anticoagulants.


Venous thromboembolism Pulmonary embolism Deep vein thrombosis Treatment 


  1. 1.
    Lilienfeld DE, Chan E, Ehland J, Godbold JH, Landrigan PJ, Marsh G (1990) Mortality from pulmonary embolism in the United States: 1962 to 1984. Chest 98:1067–1072PubMedCrossRefGoogle Scholar
  2. 2.
    Lilienfeld DE (2000) Decreasing mortality from pulmonary embolism in the United States, 1979–1996. Int J Epidemiol 29:465–469PubMedCrossRefGoogle Scholar
  3. 3.
    Kahn SR, Ginsberg JS (2004) Relationship between deep venous thrombosis and the postthrombotic syndrome. Arch Intern Med 164:17–26PubMedCrossRefGoogle Scholar
  4. 4.
    Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ (2008) Antithrombotic therapy for venous thromboembolic disease: American college of chest physicians evidence-based clinical practice guidelines (8th edition). Chest 133:454S–545SPubMedCrossRefGoogle Scholar
  5. 5.
    Hirsh J, Guyatt G, Albers G, Harrington R, Schünemann HJ (2008) Executive summary: American college of chest physicians evidence-based clinical practice guidelines (8th edition). Chest 133:71S–109SPubMedCrossRefGoogle Scholar
  6. 6.
    Barritt DW, Jordan SC (1960) Anticoagulant drugs in the treatment of pulmonary embolism. A controlled trial. Lancet 1:1309–1312PubMedCrossRefGoogle Scholar
  7. 7.
    Brandjes DP, Heijboer H, Büller HR, de Rijk M, Jagt H, ten Cate JW (1992) Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis. N Engl J Med 327:1485–1489PubMedCrossRefGoogle Scholar
  8. 8.
    Harrison L, Johnston M, Massicotte MP, Crowther M, Moffat K, Hirsh J (1997) Comparison of 5-mg and 10-mg loading does in initiation of warfarin therapy. Ann Intern Med 126:133–136PubMedGoogle Scholar
  9. 9.
    Büller HR, Davidson BL, Decousus H et al (2004) Fondaparinux or enoxaparin for the initial treatment of symptomatic deep vein thrombosis: a randomized trial. Ann Intern Med 140:867–873PubMedGoogle Scholar
  10. 10.
    Kearon C, Ginsberg JS, Julian JA et al (2006) Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism. JAMA 296:935–942PubMedCrossRefGoogle Scholar
  11. 11.
    Lim W, Dentali F, Eikelboom JW, Crowther MA (2006) Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med 144:673–684PubMedGoogle Scholar
  12. 12.
    Bates SM, Greer IA, Papinger I, Hirsh J, Ginsberg JS (2004) Use of antithrombic agents during pregnancy: the Seventh ACCP Conference on Antithrombic and Thrombolytic Therapy. Chest 126:627S–644SPubMedCrossRefGoogle Scholar
  13. 13.
    Baglin T, Luddington R, Brown K, Baglin C (2003) Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet 362:523–526PubMedCrossRefGoogle Scholar
  14. 14.
    Lim W, Crowther MA, Eikelboom JW (2006) Management of phospholipids antibody syndrome: a systematic review. JAMA 295:1050–1057PubMedCrossRefGoogle Scholar
  15. 15.
    Campbell IA, Bentley DP, Prescott RJ, Routledge PA, Shetty HG, Williamson IJ (2007) Anticoagulation for three versus six months in patients with deep vein thrombosis or pulmonary embolism, or both: randomised trial. BMJ 334:674–680PubMedCrossRefGoogle Scholar
  16. 16.
    Pinede L, Ninet J, Duhaut P et al (2001) Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis. Circulation 103:2453–2460PubMedGoogle Scholar
  17. 17.
    Garcia DA, Spyropoulos AC (2008) Update in the treatment of venous thromboembolism. Semin Respir Crit Care Med 29:40–46PubMedCrossRefGoogle Scholar
  18. 18.
    Kearon C, Gent M, Hirsh J et al (1999) A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 340:901–907PubMedCrossRefGoogle Scholar
  19. 19.
    Lee AY, Levine MN, Baker RI et al (2003) Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349:146–153PubMedCrossRefGoogle Scholar
  20. 20.
    Hull RD, Pineo GF, Brant RF et al (2006) Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med 119:1062–1072PubMedCrossRefGoogle Scholar
  21. 21.
    Deitcher SR (2003) Cancer and thrombosis: mechanisms and treatment. J Thromb Thrombolysis 16:21–31PubMedCrossRefGoogle Scholar
  22. 22.
    Kahn SR, Shbaklo H, Lamping DL et al (2008) Determinants of health-related quality of life during the 2 years following deep vein thrombosis. J Thromb Haemost 6:1105–1112PubMedCrossRefGoogle Scholar
  23. 23.
    Prandoni P, Lensing AW, Prins MH et al (2004) Below-knee elastic compression stockings to prevent the post-thrombotic syndrome: a randomized, controlled trial. Ann Intern Med 141:249–256PubMedGoogle Scholar
  24. 24.
    Wittkowsky AK, Nutescu EA, Devine EB (2008) Compression stockings to prevent post-thrombotic syndrome: a role for anticoagulation clinics? J Thromb Thrombolysis 26:248–250PubMedCrossRefGoogle Scholar
  25. 25.
    Elsharawy M, Elzayat E (2002) Early results of thrombolysis vs anticoagulation in iliofemoral venous thrombosis. A randomised clinical trial. Eur J Vasc Endovasc Surg 24:209–214PubMedCrossRefGoogle Scholar
  26. 26.
    Goldhaber SZ, Visani L, De Rosa M (1999) Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet 353:1386–1389PubMedCrossRefGoogle Scholar
  27. 27.
    Hamel E, Pacouret G, Vincentelli D et al (2001) Thrombolysis or heparin therapy in massive pulmonary embolism with right ventricular dilation: results from a 128-patient monocenter registry. Chest 120:120–125PubMedCrossRefGoogle Scholar
  28. 28.
    Fengler BT, Brady WJ (2009) Fibrinolytic therapy in pulmonary embolism: an evidence-based treatment algorithm. Am J Emerg Med 27:84–95PubMedCrossRefGoogle Scholar
  29. 29.
    Moores LK, Tapson VF (2001) Vena cava filters in pulmonary embolism. Semin Vasc Med 1:221–228PubMedCrossRefGoogle Scholar
  30. 30.
    Norris CS, Greenfield LJ, Herrmann JB (1985) Free-floating iliofemoral thrombus. A risk of pulmonary embolism. Arch Surg 120:806–808PubMedGoogle Scholar
  31. 31.
    PREPIC Study Group (2005) Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: the PREPIC (Prevention du Risque d’Embolie Pulmonaire par Interruption Cave) randomized study. Circulation 112:416–422CrossRefGoogle Scholar
  32. 32.
    Eriksson BI, Borris LC, Friedman RJ et al (2008) Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 358:2765–2775PubMedCrossRefGoogle Scholar
  33. 33.
    Lassen MR, Ageno W, Borris LC et al (2008) Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 358:2776–2786PubMedCrossRefGoogle Scholar
  34. 34.
    Eriksson BI, Dahl OE, Rosencher N et al (2007) Oral dabigatran etexilate vs subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 5:2178–2185PubMedCrossRefGoogle Scholar
  35. 35.
    Eriksson BI, Dahl OE, Rosencher N et al (2007) Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 370:949–956PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • M. Houman Fekrazad
    • 1
  • Renato D. Lopes
    • 2
  • Gregg J. Stashenko
    • 2
  • John H. Alexander
    • 2
  • David Garcia
    • 1
  1. 1.Division of Hematology/OncologyUniversity of New MexicoAlbuquerqueUSA
  2. 2.Duke Clinical Research Institute, Duke University Medical CenterDurhamUSA

Personalised recommendations